A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Subjects with International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic ...

Update Il y a 4 ans
Reference: EUCTR2011-000261-12

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Subjects with International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective is to assess the clinical efficacy of siltuximab, demonstrated by a reduction in RBC transfusions to treat the anemia of MDS.


Inclusion criteria

  • Anemia associated with Low- or Intermediate-1-Risk Myelodysplastic
  • Syndrome